Physician profile
Frank Klima
NPI 1467756809
$5,275.32
in general payments reported to CMS, 2019-2025
53 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,151 · 2022: $403 · 2023: $458 · 2024: $1,579 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,721.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $792.28 | 2021-2025 | |
| Amgen INC. | $415.34 | 2022-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $390.35 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $277.65 | 2021-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $260.56 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.40 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $194.97 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $182.00 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $164.49 | 2021-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $138.55 | 2022-2023 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $128.33 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $119.26 | 2024-2025 | |
| Exact Sciences Corporation | $105.97 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $104.07 | 2024-2025 | Zenpep, Vowst |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Klima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.